NCT05935176View on ClinicalTrials.gov

Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

PHASE4CompletedINTERVENTIONAL
Enrollment

660

Participants

Timeline

Start Date

September 20, 2023

Primary Completion Date

October 14, 2024

Study Completion Date

January 8, 2025

Conditions
Epidemic Meningitis
Interventions
BIOLOGICAL

MCV4

2 dose of MCV4 on Day 0 and Month 1

BIOLOGICAL

MCV4

2 dose of MCV4 on Day 0 and Month 3

Trial Locations (1)

Unknown

Wuzhi County Center for Disease Control and Prevention, Jiaozuo

Sponsors
All Listed Sponsors
lead

CanSino Biologics Inc.

INDUSTRY

NCT05935176 - Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) | Biotech Hunter | Biotech Hunter